Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones.

By E. Kon, A. Muraglia, A. Corsi, P. Bianco, M. Marcacci, I. Martin, A. Boyde, I. Ruspantini, P. Chistolini, M. Rocca and 3 more. Journal of Biomedical Materials Research, 2000

733 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Genetics, Urology

View Paper: https://www.semanticscholar.org/paper/d70b0854067c472ee238ae67ffc1fca0caafc4ec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Jihua Li
2. Y. Zuo
3. Huanan Wang
4. Lin Cheng
5. Sansi Ma
6. Yubao Li

In Genetics

1. A. Caplan
2. O. Ringdén

In Urology

1. A. Caplan

Citations in the corpus

• Biocompatibility and osteogenesis of biomimetic nano-hydroxyapatite/polyamide composite scaffolds for bone tissue engineering. (2007, background): “In the bone tissue engineering field, there has been a special interest on MSCs loaded onto porous scaffolds, which provide a prospective approach for the reconstruction of even large bone defects [45–49].”
• HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. (2003, background): “that MSC contribute to tissue repair and may be used in the regeneration of bone, cartilage, skeletal muscle, and myocardium [21–25].”
• Stem Cells Associated with Macroporous Bioceramics for Long Bone Repair: 6- to 7-Year Outcome of a Pilot Clinical Study (2007, unknown): “27 32 The best characterized are those derived from the bone marrow stroma, which yields a mesenchymal stem/progenitor cell population from which differentiated cells of various connective tissues can be derived.”
• Adult mesenchymal stem cells for tissue engineering versus regenerative medicine (2007, background): “Although these approaches have been described in various animal models and in limited numbers in human (Kon et al., 2000), no human MSC-based tissue engineering technology is currently clinically available.”
• The Regulation of Differentiation in Mesenchymal Stem Cells (2010, unknown): “Using HA-based bioscaffolds, it then became possible to repair segmental bone defects in vivo by using autologous MSCs, under loaded conditions, both in large animals (Kon et al. , 2000) as well as in humans in proof-of-concept studies (Quarto et al. , 2001).”